Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT01719770Phase 3Completed
Phase 3, randomised, double-blind trial comparing Rocuronium with Placebo (2 arms). Primary endpoint: Number of shivering episodes at 31 hours. Started Nov 2010; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT01719770.